OR WAIT null SECS
May 01, 2021
John Wells, MD, presents efficacy, durability, and safety findings from phase 3 YOSEMITE and RHINE trials during the virtual ARVO meeting.
April 21, 2021
Easier, more accessible functional studies have been made possible
April 02, 2021
Numerous studies will be completed during the next few years, and many new studies are being developed.
March 22, 2021
Anat Loewenstein, MD, MHA, discusses data from the Angiogenesis, Exudation, and Degeneration 2021 Virtual Symposium on angiopoietin-2/VEGF-A dual inhibition in the management of diabetic macular edema and exudative age-related macular degeneration.
March 12, 2021
Study highlights role of demographic and socioeconomic characteristics in treatment
March 01, 2021
The hope is that future analyses would show more patients completing the pathway and a lower rate of missed appointments.
February 01, 2021
The development of a novel AI-based algorithm aims to improve risk prediction for diabetic eye disease.
Insights into the pathophysiology of diabetic macular edema are providing a basis for therapeutic interventions.
January 01, 2021
Multiple challenges remain for diabetic macular edema with unmet needs to improve treatment outcomes, speed of treatment benefit, and the duration of response.
Three risk-related baseline factors identified by this analysis may be associated with a potential need for injections.
